New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
Resmed (NYSE: RMD) announced groundbreaking research published in The Lancet Respiratory Medicine showing that CPAP therapy significantly reduces mortality risk in sleep apnea patients. The largest-ever meta-analysis, analyzing over 1 million patients across 30 studies, revealed that CPAP users have a 37% lower risk of all-cause mortality and a 55% lower risk of cardiovascular-related death compared to non-users.
The study demonstrates a dose-response relationship, indicating greater survival benefits with more consistent CPAP use. This research included data from 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years.
The findings are particularly significant given that obstructive sleep apnea (OSA) affects over one billion people worldwide, with more than 80% of cases remaining undiagnosed and untreated. The study establishes CPAP therapy as a life-saving intervention that requires only air, without drugs or surgery.
Resmed (NYSE: RMD) ha annunciato una ricerca innovativa pubblicata su The Lancet Respiratory Medicine che mostra come la terapia CPAP riduca significativamente il rischio di mortalità nei pazienti con apnea notturna. La meta-analisi più ampia mai realizzata, che ha analizzato oltre 1 milione di pazienti in 30 studi, ha rivelato che gli utenti di CPAP hanno un 37% di rischio in meno di mortalità per tutte le cause e un 55% di rischio in meno di morte cardiovascolare rispetto ai non utenti.
Lo studio dimostra una relazione dose-risposta, indicando maggiori benefici in termini di sopravvivenza con un uso più costante della CPAP. Questa ricerca ha incluso dati provenienti da 10 studi controllati randomizzati e 20 studi di evidenza del mondo reale, con un periodo medio di follow-up di quasi cinque anni.
I risultati sono particolarmente significativi considerando che l'apnea ostruttiva del sonno (OSA) colpisce oltre un miliardo di persone in tutto il mondo, con più dell'80% dei casi che rimangono non diagnosticati e non trattati. Lo studio stabilisce la terapia CPAP come un intervento salvavita che richiede solo aria, senza farmaci o interventi chirurgici.
Resmed (NYSE: RMD) anunció una investigación innovadora publicada en The Lancet Respiratory Medicine que muestra que la terapia CPAP reduce significativamente el riesgo de mortalidad en pacientes con apnea del sueño. El metaanálisis más grande jamás realizado, que analizó a más de 1 millón de pacientes en 30 estudios, reveló que los usuarios de CPAP tienen un 37% menos de riesgo de mortalidad por todas las causas y un 55% menos de riesgo de muerte relacionada con enfermedades cardiovasculares en comparación con los no usuarios.
El estudio demuestra una relación dosis-respuesta, indicando mayores beneficios de supervivencia con un uso más constante de la CPAP. Esta investigación incluyó datos de 10 ensayos controlados aleatorios y 20 estudios de evidencia del mundo real, con un período medio de seguimiento de casi cinco años.
Los hallazgos son particularmente significativos dado que la apnea obstructiva del sueño (OSA) afecta a más de mil millones de personas en todo el mundo, con más del 80% de los casos permaneciendo sin diagnosticar y sin tratar. El estudio establece la terapia CPAP como una intervención que salva vidas que solo requiere aire, sin medicamentos ni cirugía.
Resmed (NYSE: RMD)는 The Lancet Respiratory Medicine에 발표된 혁신적인 연구 결과를 발표했으며, 이 연구는 CPAP 치료가 수면 무호흡증 환자의 사망 위험을 크게 줄인다는 것을 보여줍니다. 30개의 연구에서 100만 명 이상의 환자를 분석한 역사상 가장 큰 메타 분석 결과, CPAP 사용자는 비사용자에 비해 모든 원인으로 인한 사망 위험이 37% 낮고, 심혈관 관련 사망 위험이 55% 낮습니다.
이 연구는 CPAP 사용이 일관될수록 더 큰 생존 혜택이 있음을 나타내는 용량-반응 관계를 보여줍니다. 이 연구는 10개의 무작위 통제 시험과 20개의 실제 증거 연구의 데이터를 포함하며, 평균 추적 관찰 기간은 거의 5년입니다.
이 결과는 폐쇄성 수면 무호흡증(OSA)이 전 세계적으로 10억 명 이상의 사람들에게 영향을 미치며, 80% 이상의 사례가 진단되지 않고 치료되지 않고 있다는 점에서 특히 중요합니다. 이 연구는 CPAP 치료를 약물이나 수술 없이 공기만으로 이루어지는 생명을 구하는 개입으로 설정합니다.
Resmed (NYSE: RMD) a annoncé des recherches révolutionnaires publiées dans The Lancet Respiratory Medicine, montrant que la thérapie CPAP réduit significativement le risque de mortalité chez les patients souffrant d'apnée du sommeil. La plus grande méta-analyse jamais réalisée, analysant plus d'un million de patients à travers 30 études, a révélé que les utilisateurs de CPAP ont un risque de mortalité toutes causes confondues inférieur de 37% et un risque de décès lié aux maladies cardiovasculaires inférieur de 55% par rapport aux non-utilisateurs.
L'étude démontre une relation dose-réponse, indiquant de plus grands bénéfices en matière de survie avec un usage plus régulier de la CPAP. Cette recherche a inclus des données provenant de 10 essais contrôlés randomisés et de 20 études de preuves du monde réel, avec une période de suivi moyenne de près de cinq ans.
Les résultats sont particulièrement significatifs étant donné que l'apnée obstructive du sommeil (OSA) touche plus d'un milliard de personnes dans le monde, avec plus de 80% des cas restant non diagnostiqués et non traités. L'étude établit la thérapie CPAP comme une intervention salvatrice qui nécessite uniquement de l'air, sans médicaments ni chirurgie.
Resmed (NYSE: RMD) hat bahnbrechende Forschung veröffentlicht, die in The Lancet Respiratory Medicine erschienen ist, und zeigt, dass die CPAP-Therapie das Sterberisiko bei Patienten mit Schlafapnoe signifikant senkt. Die größte jemals durchgeführte Meta-Analyse, die über 1 Million Patienten aus 30 Studien analysierte, ergab, dass CPAP-Nutzer ein 37% geringeres Risiko für alle Ursachen der Sterblichkeit und ein 55% geringeres Risiko für kardiovaskulär bedingte Todesfälle im Vergleich zu Nicht-Nutzern haben.
Die Studie zeigt eine Dosis-Wirkungs-Beziehung, die größere Überlebensvorteile bei konsistenterer CPAP-Nutzung anzeigt. Diese Forschung umfasste Daten aus 10 randomisierten kontrollierten Studien und 20 Studien mit realen Beweisen, mit einer durchschnittlichen Nachbeobachtungszeit von fast fünf Jahren.
Die Ergebnisse sind besonders bedeutend, da die obstruktive Schlafapnoe (OSA) weltweit über eine Milliarde Menschen betrifft, wobei mehr als 80% der Fälle unentdeckt und unbehandelt bleiben. Die Studie etabliert die CPAP-Therapie als lebensrettende Intervention, die nur Luft benötigt, ohne Medikamente oder Operationen.
- Landmark study proves CPAP therapy significantly reduces mortality risk
- Strong evidence of 37% reduction in all-cause mortality for CPAP users
- 55% reduction in cardiovascular-related deaths demonstrates significant clinical benefit
- Large-scale study (1M+ patients) validates CPAP effectiveness
- Findings support continued market leadership in sleep apnea treatment
- Over 80% of global sleep apnea cases remain undiagnosed, indicating significant market penetration challenges
Insights
This landmark meta-analysis represents significant positive development for ResMed's core business model and long-term growth prospects. The research published in The Lancet Respiratory Medicine - demonstrating a
The study's findings directly address the substantial untapped market potential, with the article noting that over
The demonstrated dose-response relationship between CPAP usage and survival benefits aligns perfectly with ResMed's strategic investment in connected devices and monitoring solutions that track and encourage therapy adherence. This research effectively positions CPAP therapy not just as a quality-of-life improvement but as a life-extending intervention, which could meaningfully influence physician prescribing patterns, insurance coverage decisions, and patient compliance rates.
Publication in The Lancet, with its rigorous peer review process, lends exceptional credibility to these findings despite ResMed's involvement in supporting the research. The scope of the analysis - over 1 million patients across 30 studies - provides compelling statistical power that makes these results difficult to dismiss, potentially reshaping clinical practice guidelines in ResMed's favor.
Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life.
OSA affects over one billion people worldwide,1 with over
The study, led by global experts in sleep and respiratory medicine and supported by Resmed, found that people with OSA who use CPAP therapy have:
- A
37% lower risk of dying from any cause compared to those with OSA who do not use CPAP. - A
55% lower risk of dying from cardiovascular disease, reinforcing CPAP’s supportive benefits for heart health in people living with OSA. - A dose-response relationship, meaning that the more consistently CPAP is used, the greater the survival benefits for people living with OSA.
“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can improve quality of life, and this study now provides the most comprehensive evidence yet that CPAP also prolongs lives for people living with OSA.”
This meta-analysis is the largest of its kind to date, pooling data from over 1 million OSA patients across 30 studies, including 10 randomized controlled trials (RCTs) and 20 real-world evidence studies (RWEs). Researchers analyzed long-term outcomes over the average follow-up period of nearly five years, testing the hypothesis that CPAP therapy reduces both all-cause and cardiovascular mortality in OSA patients.
"The results of the study strongly suggest that CPAP therapy is a life-saving intervention for people with OSA,” said Atul Malhotra, M.D, senior author of the study, Research Chief of Pulmonary, Critical Care and Sleep Medicine at the University of California San Diego School of Medicine and Pulmonologist at UC San Diego Health. “It’s not only about sleep apnea treatment but also about supporting heart health and extending life.”
“These findings should serve as a wake-up call,” added Jean-Louis Pépin, study co-author, Professor of Clinical Physiology at Grenoble University Hospital and Director of the HP2 Laboratory INSERM U1300. “Every additional hour of CPAP treatment translates to improved chance of survival for people living with OSA. Patients who stay on CPAP therapy aren’t just breathing easier at night; they’re potentially adding years to their lives.”
To read the full study, see the publication in The Lancet Respiratory Medicine.
To learn more about how life-changing CPAP therapy can be, visit www.resmed.com/video-story-gallery.
Study authors: Adam V. Benjafield PhD; Prof Jean-Louis Pepin; Prof Peter A. Cistulli; Alison Wimms PhD; Florent Lavergne MSc; Fatima H. Sert Kuniyoshi PhD, Sibyl H. Munson PhD, Brendan Schuler BS; Shrikar Reddy Badikol MSc; Kelly C. Wolfe BS; Leslee Willes MPH; Colleen Kelly PhD; Tetyana Kendzerska MD; Dayna A. Johnson PhD; Prof Raphael Heinzer MD, Prof Chi-Hang Lee MD, Prof Atul Malhotra MD.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For Media | For Investors | |
| Caela Shay | Mike Ott or Wendy Wilson | |
| news@resmed.com | investorrelations@resmed.com |
1 Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763.
2 Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997 ;20(9):705-6
3 Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144(3): e56-e67.
FAQ
What are the mortality reduction rates shown in Resmed's (RMD) latest CPAP study?
How many patients were included in Resmed's (RMD) CPAP meta-analysis?
What is the current global prevalence of sleep apnea according to Resmed's study?
How long was the follow-up period in Resmed's (RMD) CPAP mortality study?
What type of studies were included in Resmed's (RMD) CPAP meta-analysis?
